TipRanks
Xeris Pharmaceuticals (DE:2B30)
FRANKFURT:2B30
Germany Market
2B30
Xeris Pharmaceuticals
RESEARCH TOOLSreports

Xeris Pharmaceuticals (2B30) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

2B30 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Xeris
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2B30 Stock 12 Month Forecast

Average Price Target

€11.57
▲(62.11% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Xeris Pharmaceuticals in the last 3 months. The average price target is €11.57 with a high forecast of €16.03 and a low forecast of €7.12. The average price target represents a 62.11% change from the last price of €7.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","10":"€10","17":"€17","6.5":"€6.5","13.5":"€13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.0262973,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.574548049999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.1227988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.304,8.89802286923077,9.492045738461538,10.086068607692308,10.680091476923078,11.274114346153846,11.868137215384616,12.462160084615384,13.056182953846154,13.650205823076924,14.244228692307692,14.838251561538462,15.43227443076923,{"y":16.0262973,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.304,8.555580619230769,8.80716123846154,9.058741857692308,9.310322476923076,9.561903096153845,9.813483715384615,10.065064334615384,10.316644953846154,10.568225573076923,10.819806192307691,11.07138681153846,11.32296743076923,{"y":11.574548049999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.304,8.21313836923077,8.122276738461538,8.031415107692307,7.9405534769230774,7.8496918461538465,7.758830215384616,7.667968584615385,7.577106953846154,7.486245323076923,7.395383692307693,7.304522061538462,7.213660430769231,{"y":7.1227988,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.815,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.305,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.485,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.928,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.074,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.196,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.826,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.192,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.138,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.304,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€16.03Average Price Target€11.57Lowest Price Target€7.12
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:2B30
Jenna Davidner
Barclays
Barclays
€10.68→€12.46
Buy
74.58%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA), Xeris Pharmaceuticals (NASDAQ: XERS) and Incyte (NASDAQ: INCY)
Craig-Hallum Analyst forecast on DE:2B30
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
€10.68
Buy
49.64%
Upside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and AxoGen (NASDAQ: AXGN)
H.C. Wainwright Analyst forecast on DE:2B30
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€8.9
Buy
24.70%
Upside
Reiterated
09/21/26
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
Oppenheimer Analyst forecast on DE:2B30
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€16.03
Buy
124.46%
Upside
Reiterated
09/10/26
Oppenheimer Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Piper Sandler Analyst forecast on DE:2B30
David Amsellem
Piper Sandler
Piper Sandler
€7.12
Hold
-0.24%
Downside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (NASDAQ: XERS) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on DE:2B30
Roanna Ruiz
Leerink Partners
Leerink Partners
€10.68→€14.25
Buy
99.52%
Upside
Reiterated
09/10/26
Xeris Biopharma price target raised to $16 from $12 at LeerinkXeris Biopharma price target raised to $16 from $12 at Leerink
Jefferies Analyst forecast on DE:2B30
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€8.9
Buy
24.70%
Upside
Reiterated
01/09/26
Xeris Pharmaceuticals (XERS) Gets a Buy from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:2B30
Jenna Davidner
Barclays
Barclays
€10.68→€12.46
Buy
74.58%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (NASDAQ: ESTA), Xeris Pharmaceuticals (NASDAQ: XERS) and Incyte (NASDAQ: INCY)
Craig-Hallum Analyst forecast on DE:2B30
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
€10.68
Buy
49.64%
Upside
Reiterated
09/29/26
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and AxoGen (NASDAQ: AXGN)
H.C. Wainwright Analyst forecast on DE:2B30
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€8.9
Buy
24.70%
Upside
Reiterated
09/21/26
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
Oppenheimer Analyst forecast on DE:2B30
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€16.03
Buy
124.46%
Upside
Reiterated
09/10/26
Oppenheimer Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Piper Sandler Analyst forecast on DE:2B30
David Amsellem
Piper Sandler
Piper Sandler
€7.12
Hold
-0.24%
Downside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (NASDAQ: XERS) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on DE:2B30
Roanna Ruiz
Leerink Partners
Leerink Partners
€10.68→€14.25
Buy
99.52%
Upside
Reiterated
09/10/26
Xeris Biopharma price target raised to $16 from $12 at LeerinkXeris Biopharma price target raised to $16 from $12 at Leerink
Jefferies Analyst forecast on DE:2B30
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€8.9
Buy
24.70%
Upside
Reiterated
01/09/26
Xeris Pharmaceuticals (XERS) Gets a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HROWHarrow Health
KURAKura Oncology
DNLIDenali Therapeutics
STOKStoke Therapeutics
CELCCelcuity
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xeris Pharmaceuticals

3 Months
Chase KnickerbockerCraig-Hallum
Success Rate
17/23 ratings generated profit
74%
Average Return
+22.06%
Copying Chase Knickerbocker's trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +22.06% per trade.
1 Year
Chase KnickerbockerCraig-Hallum
Success Rate
23/23 ratings generated profit
100%
Average Return
+74.16%
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.16% per trade.
2 Years
Chase KnickerbockerCraig-Hallum
Success Rate
23/23 ratings generated profit
100%
Average Return
+158.11%
Copying Chase Knickerbocker's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +158.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2B30 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
4
3
1
4
4
Buy
3
4
5
6
6
Hold
0
0
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
7
12
12
In the current month, 2B30 has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2B30 average Analyst price target in the past 3 months is 11.57.
Each month's total comprises the sum of three months' worth of ratings.

2B30 Financial Forecast

2B30 Earnings Forecast

Next quarter’s earnings estimate for 2B30 is €0.03 with a range of <€0.01 to €0.05. The previous quarter’s EPS was -€0.16. 2B30 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2B30 is €0.03 with a range of <€0.01 to €0.05. The previous quarter’s EPS was -€0.16. 2B30 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.

2B30 Sales Forecast

Next quarter’s sales forecast for 2B30 is €90.77M with a range of €89.27M to €91.95M. The previous quarter’s sales results were €82.21M. 2B30 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2B30 is €90.77M with a range of €89.27M to €91.95M. The previous quarter’s sales results were €82.21M. 2B30 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.

2B30 Stock Forecast FAQ

What is DE:2B30’s average 12-month price target, according to analysts?
Based on analyst ratings, Xeris Pharmaceuticals’s 12-month average price target is 11.57.
    What is DE:2B30’s upside potential, based on the analysts’ average price target?
    Xeris Pharmaceuticals has 62.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Xeris Pharmaceuticals a Buy, Sell or Hold?
          Xeris Pharmaceuticals has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Xeris Pharmaceuticals’s share price target?
            The average share price target for Xeris Pharmaceuticals is 11.57. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €16.03 ,and the lowest forecast is €7.12. The average share price target represents 62.11% Increase from the current price of €7.14.
              What do analysts say about Xeris Pharmaceuticals?
              Xeris Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Xeris Pharmaceuticals?
                To buy shares of DE:2B30, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.